Copyright Reports & Markets. All rights reserved.

Global Endocrine Therapy Drugs for Breast Cancer Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Tamoxifen
      • 1.4.3 Anastrozole
      • 1.4.4 Exemestane
      • 1.4.5 Letrozole
      • 1.4.6 Goserelin
      • 1.4.7 Fulvestrant
    • 1.5 Market by Application
      • 1.5.1 Global Endocrine Therapy Drugs for Breast Cancer Market Share by Application (2014-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Drug Center
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Endocrine Therapy Drugs for Breast Cancer Market Size
    • 2.2 Endocrine Therapy Drugs for Breast Cancer Growth Trends by Regions
      • 2.2.1 Endocrine Therapy Drugs for Breast Cancer Market Size by Regions (2014-2025)
      • 2.2.2 Endocrine Therapy Drugs for Breast Cancer Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Endocrine Therapy Drugs for Breast Cancer Market Size by by Players
      • 3.1.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue by by Players (2014-2019)
      • 3.1.2 Global Endocrine Therapy Drugs for Breast Cancer Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Endocrine Therapy Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.2 Endocrine Therapy Drugs for Breast Cancer Key Players Head office and Area Served
    • 3.3 Key Players Endocrine Therapy Drugs for Breast Cancer Product/Solution/Service
    • 3.4 Date of Enter into Endocrine Therapy Drugs for Breast Cancer Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size by Type (2014-2019)
    • 4.2 Global Endocrine Therapy Drugs for Breast Cancer Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Endocrine Therapy Drugs for Breast Cancer Market Size (2014-2019)
    • 5.2 Endocrine Therapy Drugs for Breast Cancer Key Players in United States
    • 5.3 United States Endocrine Therapy Drugs for Breast Cancer Market Size by Type
    • 5.4 United States Endocrine Therapy Drugs for Breast Cancer Market Size by Application

    6 Europe

    • 6.1 Europe Endocrine Therapy Drugs for Breast Cancer Market Size (2014-2019)
    • 6.2 Endocrine Therapy Drugs for Breast Cancer Key Players in Europe
    • 6.3 Europe Endocrine Therapy Drugs for Breast Cancer Market Size by Type
    • 6.4 Europe Endocrine Therapy Drugs for Breast Cancer Market Size by Application

    7 China

    • 7.1 China Endocrine Therapy Drugs for Breast Cancer Market Size (2014-2019)
    • 7.2 Endocrine Therapy Drugs for Breast Cancer Key Players in China
    • 7.3 China Endocrine Therapy Drugs for Breast Cancer Market Size by Type
    • 7.4 China Endocrine Therapy Drugs for Breast Cancer Market Size by Application

    8 Japan

    • 8.1 Japan Endocrine Therapy Drugs for Breast Cancer Market Size (2014-2019)
    • 8.2 Endocrine Therapy Drugs for Breast Cancer Key Players in Japan
    • 8.3 Japan Endocrine Therapy Drugs for Breast Cancer Market Size by Type
    • 8.4 Japan Endocrine Therapy Drugs for Breast Cancer Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Endocrine Therapy Drugs for Breast Cancer Market Size (2014-2019)
    • 9.2 Endocrine Therapy Drugs for Breast Cancer Key Players in Southeast Asia
    • 9.3 Southeast Asia Endocrine Therapy Drugs for Breast Cancer Market Size by Type
    • 9.4 Southeast Asia Endocrine Therapy Drugs for Breast Cancer Market Size by Application

    10 India

    • 10.1 India Endocrine Therapy Drugs for Breast Cancer Market Size (2014-2019)
    • 10.2 Endocrine Therapy Drugs for Breast Cancer Key Players in India
    • 10.3 India Endocrine Therapy Drugs for Breast Cancer Market Size by Type
    • 10.4 India Endocrine Therapy Drugs for Breast Cancer Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Endocrine Therapy Drugs for Breast Cancer Market Size (2014-2019)
    • 11.2 Endocrine Therapy Drugs for Breast Cancer Key Players in Central & South America
    • 11.3 Central & South America Endocrine Therapy Drugs for Breast Cancer Market Size by Type
    • 11.4 Central & South America Endocrine Therapy Drugs for Breast Cancer Market Size by Application

    12 International Players Profiles

    • 12.1 Teva
      • 12.1.1 Teva Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.1.4 Teva Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.1.5 Teva Recent Development
    • 12.2 Amneal Pharms
      • 12.2.1 Amneal Pharms Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.2.4 Amneal Pharms Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.2.5 Amneal Pharms Recent Development
    • 12.3 AstraZeneca
      • 12.3.1 AstraZeneca Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.3.4 AstraZeneca Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.3.5 AstraZeneca Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.4.4 Novartis Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Intas Pharmaceuticals
      • 12.5.1 Intas Pharmaceuticals Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.5.4 Intas Pharmaceuticals Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.5.5 Intas Pharmaceuticals Recent Development
    • 12.6 Chemo
      • 12.6.1 Chemo Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.6.4 Chemo Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.6.5 Chemo Recent Development
    • 12.7 Accure Labs
      • 12.7.1 Accure Labs Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.7.4 Accure Labs Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.7.5 Accure Labs Recent Development
    • 12.8 Natco
      • 12.8.1 Natco Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.8.4 Natco Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.8.5 Natco Recent Development
    • 12.9 Zydus Pharmaceuticals
      • 12.9.1 Zydus Pharmaceuticals Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.9.4 Zydus Pharmaceuticals Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.9.5 Zydus Pharmaceuticals Recent Development
    • 12.10 Sanofi
      • 12.10.1 Sanofi Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Endocrine Therapy Drugs for Breast Cancer Introduction
      • 12.10.4 Sanofi Revenue in Endocrine Therapy Drugs for Breast Cancer Business (2014-2019)
      • 12.10.5 Sanofi Recent Development
    • 12.11 Pfizer
    • 12.12 Mylan
    • 12.13 Wockhardt
    • 12.14 Cipla
    • 12.15 Actiza Pharmaceutical
    • 12.16 Hikma Pharmaceuticals
    • 12.17 Shanghai Forward Technology
    • 12.18 Bayer
    • 12.19 Liaoning Kangtai Pharmaceutical
    • 12.20 Fu 'an Pharmaceutical Group
    • 12.21 Apotex
    • 12.22 Taro
    • 12.23 Sun Phamaceutical
    • 12.24 Intas Pharmaceuticals
    • 12.25 Chemo
    • 12.26 Accure Labs
    • 12.27 Sun Pharmaceutical

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Endocrine Therapy Drugs for Breast Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Endocrine Therapy Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Endocrine Therapy Drugs for Breast Cancer development in United States, Europe and China.

      The key players covered in this study
      Teva
      Amneal Pharms
      AstraZeneca
      Novartis
      Intas Pharmaceuticals
      Chemo
      Accure Labs
      Natco
      Zydus Pharmaceuticals
      Sanofi
      Pfizer
      Mylan 
      Wockhardt
      Cipla
      Actiza Pharmaceutical
      Hikma Pharmaceuticals
      Shanghai Forward Technology
      Bayer
      Liaoning Kangtai Pharmaceutical
      Fu 'an Pharmaceutical Group
      Apotex
      Taro
      Sun Phamaceutical
      Intas Pharmaceuticals
      Chemo
      Accure Labs
      Sun Pharmaceutical

      Market segment by Type, the product can be split into
      Tamoxifen
      Anastrozole
      Exemestane
      Letrozole
      Goserelin
      Fulvestrant

      Market segment by Application, split into
      Hospital
      Clinic
      Drug Center
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Endocrine Therapy Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players.
      To present the Endocrine Therapy Drugs for Breast Cancer development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Endocrine Therapy Drugs for Breast Cancer are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now